TSO₃ expands its market presence at the 36th World Medical Forum

December 14, 2004

Québec City, December 14, 2004 – Representatives from TSO3 inc.’s (“TSO3”)(TSX: TOS)  Marketing and MTP (Manufacturing Testing Program) recently attended MEDICA 2004 in Dusseldorf, Germany, from November 23 to 28, 2004. MEDICA is the world’s largest medical fair with 4300 exhibitors this year from 67 countries, with 136,000 in attendance.

“We were very delighted to hear the manufacturer’s very positive acceptance to the ozone technology as a new low temperature method for instruments sterilization”, said James W. Tatalick, consultant with TSO3 and MTP founder. “We can already notice the benefits of attending that major event in the healthcare sector”.

TSO3 met the leading medical device manufacturers (MDM) to share information on the status of its North American referral sites and on devices being processed in the 125L Ozone Sterilizers.  The management team also met to discuss TSO3’s latest developments in technology to improve quality and durability of MIS (Minimally Invasive Surgery) medical devices with all oxidizing technologies.

TSO3’s goal was to reinforce already good relationships with leading MDM but also to establish new and pro-active partnerships with device manufacturers based on direction from their Customer trial sites. All device manufacturers were enthusiastic about participating in the MTP and many committed to have their devices validated with the TSO3 125L Ozone Sterilizer in the very short term.  Moreover, TSO3’s was assured of MDM’s support in its commercialization efforts and in the implementation of TSO3’s breakthrough technology for their mutual customers in Canada and the US.

The team also researched TSO3’s market potential through the addition of capital and consumable accessory products to enhance TSO3’s present product line offering. TSO3 believes that these additional products will offer a turnkey solution for its customers and could also be used with other sterilization technologies. 

More about MEDICA and the 2004 Edition

MEDICA is the world’s largest medical technology tradeshow.  The event attracts manufacturers, doctors, hospital administrators, buyers, agents, distributors, suppliers, wholesalers, retailers and government delegations as well as trade press and trade association representatives from around the world.

The event was able to post new top results in 2004: 136,000 trade visitors (2003: 134,700) came to Düsseldorf to the 36th World Medical Forum to gather information on the latest products, services and techniques for the entire spectrum of in and outpatient care. The share of international visitors once again rose significantly (38%). Higher numbers of visitors came from China, Taiwan, India, Russia as well as from the new EU member states.

For more information on MEDICA:http://www2.medica.de/cipp/md_medica/custom/pub/content,lang,2/oid,155/ticket,g_u_e_s_t

About TSO3

TSO3 Inc. is located in Québec City, Québec, Canada, and was founded in 1998. TSO3 currently has 47 employees, 17 of whom work exclusively in the Research and Development department. The Company’s mission is to develop and market innovative and comprehensive sterilization solutions.

TSO3 has perfected an innovative sterilization process using ozone as the sterilizing agent. The first product based on this technological platform is the 125L Ozone Sterilizer, which is intended for hospital sterilization units. The 125L – named after its 125-litre/4.3-cubic-foot capacity – was designed to sterilize the new generation of surgical and diagnostic instruments made of non-heat-resistant materials, mainly polymers. The ozone sterilization process is a safe, efficient, fast and cost-effective response to evolving sterilization needs.

The 125L Ozone Sterilizer by TSO3 was cleared for commercialization by Health Canada and more recently by the U.S. Food and Drug Administration (FDA). TSO3 expects the first sales in 2005.

The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of any financing undertaken by TSO3,are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other risks and uncertainties.

The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it.

- 30 -